The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells

The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function

(2019) Stalin Chellappa et al.   JOURNAL OF IMMUNOLOGY

Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia

(2018) Pavlina Janovska et al.   BLOOD

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

(2018) Michael Hallek et al.   BLOOD

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

(2018) Howard A Burris et al.   LANCET ONCOLOGY

Targeting the PI3K pathway in cancer: are we making headway?

(2018) Filip Janku et al.   Nature Reviews Clinical Oncology

PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma

(2017) Benjamin L. Lampson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow

(2017) I. B. Greenwell et al.   Expert Review of Anticancer Therapy

Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment

(2017) A Paulus et al.   Blood Cancer Journal

PI3Kγ Activates Integrin α 4 and Promotes Immune Suppressive Myeloid Cell Polarization during Tumor Progression

(2017) Philippe Foubert et al.   Cancer Immunology Research

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies

(2016) Changchun Deng et al.   BLOOD

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

(2016) B. L. Lampson et al.   BLOOD

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

PI3K signaling pathway in normal B cells and indolent B-cell malignancies

(2016) Georgios Pongas et al.   SEMINARS IN ONCOLOGY

GARP: a surface molecule of regulatory T cells that is involved in the regulatory function and TGF-β releasing

(2016) Liping Sun et al.   Oncotarget

Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma

(2015) Shuang Q. Zhang et al.   BRITISH JOURNAL OF HAEMATOLOGY

FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma

(2015) B. W. Miller et al.   CLINICAL CANCER RESEARCH

The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL

(2015) K Balakrishnan et al.   LEUKEMIA

Management of adverse events associated with idelalisib treatment: expert panel opinion

(2015) Steven E. Coutré et al.   LEUKEMIA & LYMPHOMA

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells

(2014) S. Dong et al.   BLOOD

Casein kinase 1 and Wnt/β-catenin signaling

(2014) Cristina-Maria Cruciat   CURRENT OPINION IN CELL BIOLOGY

Canonical Wnt Signaling Negatively Modulates Regulatory T Cell Function

(2013) Jorg van Loosdregt et al.   IMMUNITY

The Role of Regulatory T Cells in the Biology of Graft Versus Host Disease

(2013) Amy J. Beres et al.   Frontiers in Immunology

The Role of the PI3K Signaling Pathway in CD4+ T Cell Differentiation and Function

(2012) Jonathan M. Han et al.   Frontiers in Immunology

Coordinated Action of CK1 Isoforms in Canonical Wnt Signaling

(2011) B. del Valle-Perez et al.   MOLECULAR AND CELLULAR BIOLOGY

Phosphatidylinositol 3-kinase-  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

(2010) S. E. M. Herman et al.   BLOOD

Wnt/ -Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy

(2010) L. Gattinoni et al.   CLINICAL CANCER RESEARCH

Role of PI3K in the generation and survival of B cells

(2010) Markus Werner et al.   IMMUNOLOGICAL REVIEWS

Selective Inhibition of Casein Kinase 1  Minimally Alters Circadian Clock Period

(2009) K. M. Walton et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

(2009) Luca Gattinoni et al.   NATURE MEDICINE

E -TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction

(2009) G. Gorgun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA